Brightgene Bio-Medical Technology Co., Ltd. (688166.SH): The BGM0504 drug has been approved to conduct clinical trials in overweight/obese adult patients.

Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) announced that its wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Borui Pharmaceutical"), recently received a "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration (NMPA), approving the clinical trial of BGM0504 tablets in adult overweight/obese patients. BGM0504 is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors developed by the company, which can stimulate the downstream pathways of GIP and GLP-1, resulting in biological effects such as controlling blood sugar, weight loss, and treating non-alcoholic fatty liver disease (NASH), demonstrating potential for the treatment of various metabolic diseases. BGM0504 injection is currently in Phase III clinical trials in China for the indications of type 2 diabetes and weight loss, while BGM0504 tablets are the oral formulation of BGM0504. As of the date of this announcement, there are no similar oral formulations targeting the same receptors approved for market globally.